Countywide counts of newborn hospital stays with Neonatal Abstinence Syndrome (NAS) and countywide rates of newborn hospital stays with (NAS) per 1,000 newborn stays. Neonatal Abstinence Syndrome, or neonatal drug withdrawal, is an array of problems that develops shortly after birth in newborns who were exposed to addictive drugs, most often opioids, while in the mother’s womb. Withdrawal signs develop because these newborns are no longer exposed to the drug for which they have become physically dependent. This analysis is restricted to newborns with Pennsylvania-state residence who were hospitalized in Pennsylvania hospitals.
Disclaimer: Pennsylvania Health Care Cost Containment Council (PHC4) database contains statewide hospital discharge data submitted to PHC4 by Pennsylvania hospitals. Every reasonable effort has been made to ensure the accuracy of the information obtained from the Uniform Claims and Billing Form (UB-82/92/04) data elements. Computer collection edits and validation edits provide opportunity to correct specific errors that may have occurred prior to, during or after submission of data. The ultimate responsibility for data accuracy lies with individual providers. PHC4 agents and staff make no representation, guarantee, or warranty, expressed or implied that the data received from the hospitals are error-free, or that the use of this data will prevent differences of opinion or disputes with those who use published reports or purchased data. PHC4 will bear no responsibility or liability for the results or consequences of its use.

Statewide rates of newborn hospital stays with Neonatal Abstinence Syndrome (NAS) per 1,000 newborn stays.
Neonatal Abstinence Syndrome, or neonatal drug withdrawal, is an array of problems that develops shortly after birth in newborns who were exposed to addictive drugs, most often opioids, while in the mother’s womb. Withdrawal signs develop because these newborns are no longer exposed to the drug for which they have become physically dependent.
This analysis is restricted to newborns with Pennsylvania-state residence who were hospitalized in Pennsylvania hospitals.

Disclaimer:
PHC4’s database contains statewide hospital discharge data submitted to PHC4 by Pennsylvania hospitals. Every reasonable effort has been made to ensure the accuracy of the information obtained from the Uniform Claims and Billing Form (UB-82/92/04) data elements. Computer collection edits and validation edits provide opportunity to correct specific errors that may have occurred prior to, during or after submission of data. The ultimate responsibility for data accuracy lies with individual providers.
PHC4 agents and staff make no representation, guarantee, or warranty, expressed or implied that the data received from the hospitals are error-free, or that the use of this data will prevent differences of opinion or disputes with those who use published reports or purchased data. PHC4 will bear no responsibility or liability for the results or consequences of its use.

Mean Length of Stay (LOS) for all Pennsylvania general acute care hospital stays for newborns, categorized by the presence or absence of Neonatal Abstinence Syndrome (NAS).
Neonatal Abstinence Syndrome, or neonatal drug withdrawal, is an array of problems that develops shortly after birth in newborns who were exposed to addictive drugs, most often opioids, while in the mother’s womb. Withdrawal signs develop because these newborns are no longer exposed to the drug for which they have become physically dependent.
This analysis is restricted to newborns with Pennsylvania-state residence who were hospitalized in Pennsylvania hospitals. Additionally, hospital stays with rehabilitation revenue codes and hospital stays that ended in a transfer or mortality were excluded.

Disclaimer:
PHC4’s database contains statewide hospital discharge data submitted to PHC4 by Pennsylvania hospitals. Every reasonable effort has been made to ensure the accuracy of the information obtained from the Uniform Claims and Billing Form (UB-82/92/04) data elements. Computer collection edits and validation edits provide opportunity to correct specific errors that may have occurred prior to, during or after submission of data. The ultimate responsibility for data accuracy lies with individual providers.
PHC4 agents and staff make no representation, guarantee, or warranty, expressed or implied that the data received from the hospitals are error-free, or that the use of this data will prevent differences of opinion or disputes with those who use published reports or purchased data. PHC4 will bear no responsibility or liability for the results or consequences of its use.

Percent of Pennsylvania newborn hospital stays, categorized by the presence or absence of Neonatal Abstinence Syndrome (NAS), with Medicaid as the Anticipated Primary Payer.
Neonatal Abstinence Syndrome, or neonatal drug withdrawal, is an array of problems that develops shortly after birth in newborns who were exposed to addictive drugs, most often opioids, while in the mother’s womb. Withdrawal signs develop because these newborns are no longer exposed to the drug for which they have become physically dependent.
This analysis is restricted to newborns with Pennsylvania-state residence who were hospitalized in Pennsylvania hospitals.

Disclaimer:
PHC4’s database contains statewide hospital discharge data submitted to PHC4 by Pennsylvania hospitals. Every reasonable effort has been made to ensure the accuracy of the information obtained from the Uniform Claims and Billing Form (UB-82/92/04) data elements. Computer collection edits and validation edits provide opportunity to correct specific errors that may have occurred prior to, during or after submission of data. The ultimate responsibility for data accuracy lies with individual providers.
PHC4 agents and staff make no representation, guarantee, or warranty, expressed or implied that the data received from the hospitals are error-free, or that the use of this data will prevent differences of opinion or disputes with those who use published reports or purchased data. PHC4 will bear no responsibility or liability for the results or consequences of its use.